MA34135B1 - Protéines de liaison à un antigène spécifiques pour un composant p de substance amyloïde sérique - Google Patents

Protéines de liaison à un antigène spécifiques pour un composant p de substance amyloïde sérique

Info

Publication number
MA34135B1
MA34135B1 MA35252A MA35252A MA34135B1 MA 34135 B1 MA34135 B1 MA 34135B1 MA 35252 A MA35252 A MA 35252A MA 35252 A MA35252 A MA 35252A MA 34135 B1 MA34135 B1 MA 34135B1
Authority
MA
Morocco
Prior art keywords
antigen
binding proteins
component
serine
proteins specific
Prior art date
Application number
MA35252A
Other languages
English (en)
Inventor
Tejinder Kaur Bhinder
Susannah Karen Ford
Volker Germaschewski
Alan Peter Lewis
Mark Brian Pepys
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43881068&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34135(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA34135B1 publication Critical patent/MA34135B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA PRÉSENTE INVENTION A TRAIT À DES PROTÉINES DE LIAISON À UN ANTIGÈNE, TELLES QUE LES ANTICORPS, QUI SE LIENT À UN COMPOSANT P DE SUBSTANCE AMYLOÏDE SÉRIQUE (SAP) ; À DES POLYNUCLÉOTIDES CODANT LESDITES PROTÉINES DE LIAISON À UN ANTIGÈNE ; À DES COMPOSITIONS PHARMACEUTIQUES COMPRENANT LESDITES PROTÉINES DE LIAISON À UN ANTIGÈNE ET À DES PROCÉDÉS DE FABRICATION. LA PRÉSENTE INVENTION A ÉGALEMENT TRAIT À L'UTILISATION DESDITES PROTÉINES DE LIAISON À UN ANTIGÈNE DANS LE CADRE DU TRAITEMENT OU DE LA PROPHYLAXIE DE MALADIES ASSOCIÉES AU DÉPÔT DE SUBSTANCE AMYLOÏDE, NOTAMMENT L'AMYLOSE SYSTÉMIQUE, L'AMYLOSE LOCALE, LA MALADIE D'ALZHEIMER ET LE DIABÈTE DE TYPE 2.
MA35252A 2010-03-03 2011-03-01 Protéines de liaison à un antigène spécifiques pour un composant p de substance amyloïde sérique MA34135B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30995710P 2010-03-03 2010-03-03
PCT/EP2011/053038 WO2011107480A1 (fr) 2010-03-03 2011-03-01 Protéines de liaison à un antigène spécifiques pour un composant p de substance amyloïde sérique

Publications (1)

Publication Number Publication Date
MA34135B1 true MA34135B1 (fr) 2013-04-03

Family

ID=43881068

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35252A MA34135B1 (fr) 2010-03-03 2011-03-01 Protéines de liaison à un antigène spécifiques pour un composant p de substance amyloïde sérique

Country Status (39)

Country Link
EP (2) EP2542261B1 (fr)
JP (2) JP5922592B2 (fr)
KR (1) KR101817265B1 (fr)
CN (1) CN102858371B (fr)
AR (1) AR080432A1 (fr)
AU (1) AU2011223048C1 (fr)
BR (1) BR112012021926A2 (fr)
CA (1) CA2789557A1 (fr)
CL (1) CL2012002418A1 (fr)
CO (1) CO6602134A2 (fr)
CR (1) CR20120491A (fr)
CY (2) CY1118046T1 (fr)
DK (2) DK3025729T3 (fr)
DO (1) DOP2012000232A (fr)
EA (1) EA026375B1 (fr)
ES (2) ES2593454T3 (fr)
HK (2) HK1173959A1 (fr)
HR (2) HRP20161096T1 (fr)
HU (1) HUE028960T2 (fr)
IL (2) IL221418A (fr)
JO (1) JO3188B1 (fr)
LT (2) LT2542261T (fr)
MA (1) MA34135B1 (fr)
ME (1) ME02491B (fr)
MX (1) MX340350B (fr)
MY (1) MY159255A (fr)
NZ (1) NZ601763A (fr)
PE (1) PE20130040A1 (fr)
PL (2) PL3025729T3 (fr)
PT (2) PT2542261T (fr)
RS (2) RS57708B1 (fr)
SG (2) SG10201500382SA (fr)
SI (2) SI2542261T1 (fr)
SM (1) SMT201600337B (fr)
TW (1) TWI558409B (fr)
UA (1) UA108227C2 (fr)
UY (1) UY33258A (fr)
WO (1) WO2011107480A1 (fr)
ZA (1) ZA201206529B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2782333C (fr) 2009-12-02 2019-06-04 Imaginab, Inc. Minobodies j591 et cys-diabodies pour le ciblage de l'antigene membranaire specifique de la prostate humaine (psma), et procedes d'utilisation
AU2013364043B2 (en) * 2012-12-21 2018-01-04 Seagen Inc. Anti-NTB-A antibodies and related compositions and methods
CN103239713A (zh) * 2013-05-28 2013-08-14 东南大学 一种糖尿病肾病微炎症小鼠模型的建立方法
GB201407506D0 (en) 2014-04-29 2014-06-11 Glaxosmithkline Ip Dev Ltd Novel compound
US9737505B2 (en) * 2014-04-29 2017-08-22 Glaxosmithkline Intellectual Property Development Limited Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline
AU2016304764C1 (en) 2015-08-07 2023-06-01 Imaginab, Inc. Antigen binding constructs to target molecules
WO2018147960A1 (fr) 2017-02-08 2018-08-16 Imaginab, Inc. Séquences d'extension pour dianticorps
WO2019185502A1 (fr) 2018-03-26 2019-10-03 Glaxosmithkline Intellectual Property Development Limited Anticorps comprenant du sulfoxyde de méthionine au niveau de l'interface ch2-ch3

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
EP0307434B2 (fr) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Anticorps alteres
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
EP0402226A1 (fr) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Vecteurs de transformation de la levure yarrowia
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
AU668423B2 (en) 1992-08-17 1996-05-02 Genentech Inc. Bispecific immunoadhesins
RU2139092C1 (ru) 1993-06-03 1999-10-10 Терапьютик Антибодиз Инк. Фрагменты антител в терапии
GB9317120D0 (en) * 1993-08-17 1993-09-29 Royal Postgrad Med School Human serum amyloid p component
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5795737A (en) 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
ES2274566T3 (es) 1997-02-07 2007-05-16 MERCK & CO., INC. Genes gag del vih sinteticos.
PT915088E (pt) * 1997-10-31 2003-01-31 Hoffmann La Roche Derivados de d-prolina
GB9806530D0 (en) 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
JP4668498B2 (ja) 1999-10-19 2011-04-13 協和発酵キリン株式会社 ポリペプチドの製造方法
EP1539233B1 (fr) 2001-07-12 2011-04-27 FOOTE, Jefferson Anticorps super humanises
CA2838062C (fr) 2001-08-03 2015-12-22 Roche Glycart Ag Variants de glycosylation d'anticorps presentant une cytotoxicite cellulaire accrue dependante des anticorps
US6903129B2 (en) 2001-12-14 2005-06-07 Hoffman-La Roche Inc. D-proline prodrugs
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
DK2345671T3 (en) 2002-09-27 2016-02-15 Xencor Inc Optimized Fc variants and methods for their formation
JP4819364B2 (ja) 2002-12-23 2011-11-24 ウイリアム、マーシュ、ライス、ユーニヴァーサティ 線維細胞形成阻害の検出方法、ならびに線維細胞形成を増強する方法および化合物
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
WO2004099173A1 (fr) * 2003-05-12 2004-11-18 Theracarb Inc. Inhibiteurs polyvalents de la composante p des amyloides seriques
CA2573745A1 (fr) 2004-07-21 2007-01-12 Glycofi, Inc. Immunoglobulines contenant principalement un glycoforme de type glcnac2man3glcnac2
GB0712503D0 (en) 2007-06-27 2007-08-08 Therapeutics Pentraxin Ltd Use
WO2009155962A1 (fr) * 2008-06-27 2009-12-30 Pentraxin Therapeutics Limited Utilisation

Also Published As

Publication number Publication date
CY1118046T1 (el) 2017-05-17
UA108227C2 (xx) 2015-04-10
ZA201206529B (en) 2018-12-19
SMT201600337B (it) 2016-11-10
EP2542261A1 (fr) 2013-01-09
KR101817265B1 (ko) 2018-01-10
LT3025729T (lt) 2018-12-10
JP2013521252A (ja) 2013-06-10
MX340350B (es) 2016-07-06
EA201290671A1 (ru) 2013-05-30
CO6602134A2 (es) 2013-01-18
HUE028960T2 (en) 2017-01-30
DK2542261T3 (en) 2016-09-19
CA2789557A1 (fr) 2011-09-09
JP2016154535A (ja) 2016-09-01
UY33258A (es) 2011-09-30
EA026375B1 (ru) 2017-04-28
EP3025729A1 (fr) 2016-06-01
ES2593454T3 (es) 2016-12-09
EP2542261B1 (fr) 2016-07-06
JP5922592B2 (ja) 2016-05-24
PL2542261T3 (pl) 2016-12-30
PL3025729T3 (pl) 2019-02-28
ES2699078T3 (es) 2019-02-07
PT3025729T (pt) 2018-11-30
NZ601763A (en) 2014-08-29
JP6236478B2 (ja) 2017-11-22
HK1223292A1 (zh) 2017-07-28
CY1120803T1 (el) 2019-12-11
AU2011223048B2 (en) 2013-12-19
TWI558409B (zh) 2016-11-21
WO2011107480A1 (fr) 2011-09-09
CR20120491A (es) 2013-02-20
CL2012002418A1 (es) 2013-03-08
AU2011223048C1 (en) 2018-06-21
RS55133B1 (sr) 2016-12-30
KR20130027483A (ko) 2013-03-15
MX2012010129A (es) 2012-09-12
BR112012021926A2 (pt) 2020-08-25
IL221418A (en) 2017-03-30
CN102858371B (zh) 2017-03-01
AR080432A1 (es) 2012-04-11
TW201143789A (en) 2011-12-16
SG183316A1 (en) 2012-09-27
IL251031A (en) 2017-11-30
ME02491B (fr) 2017-02-20
LT2542261T (lt) 2016-09-26
JO3188B1 (ar) 2018-03-08
SG10201500382SA (en) 2015-03-30
MY159255A (en) 2016-12-30
AU2011223048A1 (en) 2012-10-04
SI2542261T1 (sl) 2016-11-30
PT2542261T (pt) 2016-09-27
HRP20161096T1 (hr) 2016-11-04
IL221418A0 (en) 2012-10-31
DK3025729T3 (en) 2018-11-26
EP3025729B1 (fr) 2018-09-12
SI3025729T1 (sl) 2018-11-30
PE20130040A1 (es) 2013-02-09
RS57708B1 (sr) 2018-12-31
IL251031A0 (en) 2017-04-30
HRP20181666T1 (hr) 2018-12-14
CN102858371A (zh) 2013-01-02
DOP2012000232A (es) 2013-01-15
HK1173959A1 (zh) 2013-05-31

Similar Documents

Publication Publication Date Title
MA34135B1 (fr) Protéines de liaison à un antigène spécifiques pour un composant p de substance amyloïde sérique
MA42622B1 (fr) Agents de liaison à tigit et leurs utilisations
MA40801A1 (fr) Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123
MA44312A (fr) Anticorps et leurs méthodes d'utilisation
MA30353B1 (fr) Anticorps se liant à la protéine tyrosine phosphatase bêta humaine (hptpbêta) et utilisations correspondantes.
MA33402B1 (fr) Compositions et procédés de ciblage de la proteine c3b de complément par des anticorps
MA40041B1 (fr) Anticorps anti-gitr et leurs procédés d'utilisation
MA35174B1 (fr) Molécules de liaison des cd3 capables de se lier aux cd3 humaines et non humaines
TW200642694A (en) Anti-M-CSF antibody compositions
MA42542B1 (fr) Molécules se liant à pd-1 et méthodes d'utilisation correspondantes
BRPI0518994A2 (pt) anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas
MA37761A1 (fr) Protéines de liaison à un antigène antagoniste d'un double récepteur et leurs utilisations
MA30384B1 (fr) Therapies combinatoires
MA30470B1 (fr) Compositions pharmaceutiques d'anticorps anti-cd40 antagoniste.
MA31092B1 (fr) Anticorps humains contre le delta-like ligand 4 humain.
MX2022005782A (es) Anticuerpos monoclonales contra la proteina amiloide beta y usos de los mismos.
EA200800355A1 (ru) Нейтрализующие антитела человека против b7rp1
MA44334A (fr) Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
MA34175B1 (fr) Anticorps anti-cxcr4 humanisés pour le traitement de cancer
MA33285B1 (fr) Anticorps anti-cxcr4 pour le traitement du vih
WO2008121615A3 (fr) Formulation d'anticorps
ATE478336T1 (de) Immunologische assays und antikörper für das anti-müller-hormon
MA30632B1 (fr) Anticorps humanisé
MA30156B1 (fr) Immunoglobulines
MA33381B1 (fr) Proteine de liaison a il-13